XML 21 R12.htm IDEA: XBRL DOCUMENT v3.23.2
Balance Sheet Accounts
 6 Months Ended
Jun. 30, 2023
Balance Sheet Related Disclosures [Abstract]  
Balance Sheet Accounts Balance Sheet Accounts
Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consist of the following:
June 30, December 31,
20232022
Prepaid income taxes$2,110 $90 
Prepaid FDA user fee and advances to clinical research organization762 3,022 
Prepaid insurance1,385 258 
Advances to commercial manufacturers4,947 5,464 
Prepaid R&D
106 106 
Pass-through receivables1,144 1,001 
All other3,820 3,259 
Total prepaid expenses and other current assets$14,274 $13,200 

Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities consist of the following:
June 30, December 31,
20232022
Accrued product sales reserves$41,345 $33,000 
Income taxes payable1,158 5,182 
Royalties payable to commercial partners6,446 7,205 
Accrued salary and other compensation 4,774 5,293 
Accrued professional fees2,251 5,541 
Accrued research & development2,022 1,549 
Current portion of lease liability1,422 1,534 
Inventory received but not invoiced 2,456 6,779 
Forward liability related to Enalare— 4,063 
Pemfexy royalty buy-down payable— 15,000 
Accrued other 616 698 
Total accrued expenses and other current liabilities$62,490 $85,844 

Leases
We lease office space in Woodcliff Lake, New Jersey for our principal office under an amended lease agreement through June 2025. We also lease a lab space in Cambridge, Massachusetts under a lease agreement through April 2024, office space located in Indianapolis, Indiana through November 2023, and an office space located in Palm Beach Gardens, Florida through October 2024. All of our leases are classified as operating leases and have remaining lease terms of approximately 1.7 years. The principal office and the lab space leases include renewal options to extend the lease for up to 5 years. Furthermore, we have not elected the practical expedient to separate lease and non-lease components for all classes of underlying assets.
The table below summarizes our total lease costs included in the condensed consolidated financial statements, as well as other required quantitative disclosures (in thousands):

June 30, 2023December 31, 2022
Operating lease cost$845 $1,507 
Total lease cost$845 $1,507 
Other information:
Cash paid for amounts included in the measurement of lease liabilities
     Operating cash flows for operating leases$845 $1,507 
Right-of-use assets obtained in exchange for new operating lease liabilities$— $— 
Weighted-average remaining lease term - operating leases 1.7 years2.1 years
Weighted-average discount rate - operating leases 6.0 %6.0 %

Balance Sheet Classification as of June 30, 2023:
Current lease liabilities (included within Accrued expenses and other liabilities)$1,422 
Long-term lease liabilities (included within Other long-term liabilities)839 
Total lease liabilities$2,261